Form 4 for CRSP CRISPR Therapeutics AG
Accepted 2022-03-14 00:00:00 ET · period of report 2022-03-10 · accession 0001209191-22-018609 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-03-14 | 2022-03-11+ | CRSP | KASINGER JAMES R. | GC, Sec | F - Tax | $61.91 | -2,360 | 45.2K | -5% | -$146.1K |
| DM | 2022-03-14 | 2022-03-10+ | CRSP | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +5,084 | 46.5K | +12% | — |
| DM | 2022-03-14 | 2022-03-10+ | CRSP | KASINGER JAMES R. | GC, Sec | M - OptEx | — | -5,084 | 2,833 | -64% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2022-03-14 | F | D | 1,039 | $61.08 | 46,429 | D | — | — | (F3) Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. |
| 2 | Common | Common Shares | 2022-03-11 | M | A | 2,250 | — | 47,468 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. |
| 3 | Common | Common Shares | 2022-03-11 | F | D | 1,321 | $62.56 | 45,218 | D | — | — | (F3) Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. |
| 4 | Common | Common Shares | 2022-03-10 | M | A | 2,834 | — | 46,539 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. (F2) Includes 163 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. |
| 5 | Derivative | Restricted Stock Units | 2022-03-11 | M | D | 2,250 | — | 6,750 | D | — · — to — | 2,250 Common Shares | (F1) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. (F5) This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. |
| 6 | Derivative | Restricted Stock Units | 2022-03-10 | M | D | 2,834 | — | 2,833 | D | — · — to — | 2,834 Common Shares | (F1) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. (F4) This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. |